X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs DIVIS LABORATORIES - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD DIVIS LABORATORIES WYETH LTD/
DIVIS LABORATORIES
 
P/E (TTM) x 27.7 31.7 87.4% View Chart
P/BV x 5.3 5.1 103.9% View Chart
Dividend Yield % 1.3 1.0 132.4%  

Financials

 WYETH LTD   DIVIS LABORATORIES
EQUITY SHARE DATA
    WYETH LTD
Mar-13
DIVIS LABORATORIES
Mar-17
WYETH LTD/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,0441,222 85.5%   
Low Rs818784 104.3%   
Sales per share (Unadj.) Rs298.6153.1 195.0%  
Earnings per share (Unadj.) Rs57.239.9 143.3%  
Cash flow per share (Unadj.) Rs58.444.6 131.0%  
Dividends per share (Unadj.) Rs17.0010.00 170.0%  
Dividend yield (eoy) %1.81.0 183.1%  
Book value per share (Unadj.) Rs249.5201.8 123.6%  
Shares outstanding (eoy) m22.72265.47 8.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.16.6 47.6%   
Avg P/E ratio x16.325.1 64.8%  
P/CF ratio (eoy) x15.922.5 70.9%  
Price / Book Value ratio x3.75.0 75.1%  
Dividend payout %29.725.0 118.6%   
Avg Mkt Cap Rs m21,157266,266 7.9%   
No. of employees `0000.59.7 5.1%   
Total wages/salary Rs m4004,687 8.5%   
Avg. sales/employee Rs Th13,787.44,175.0 330.2%   
Avg. wages/employee Rs Th813.0481.5 168.8%   
Avg. net profit/employee Rs Th2,643.31,089.3 242.7%   
INCOME DATA
Net Sales Rs m6,78340,643 16.7%  
Other income Rs m353749 47.1%   
Total revenues Rs m7,13641,392 17.2%   
Gross profit Rs m1,61714,460 11.2%  
Depreciation Rs m271,233 2.2%   
Interest Rs m623 24.3%   
Profit before tax Rs m1,93813,953 13.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6323,349 18.9%   
Profit after tax Rs m1,30110,604 12.3%  
Gross profit margin %23.835.6 67.0%  
Effective tax rate %32.624.0 135.9%   
Net profit margin %19.226.1 73.5%  
BALANCE SHEET DATA
Current assets Rs m6,98440,105 17.4%   
Current liabilities Rs m2,0566,595 31.2%   
Net working cap to sales %72.682.5 88.1%  
Current ratio x3.46.1 55.9%  
Inventory Days Days99119 83.7%  
Debtors Days Days2481 29.7%  
Net fixed assets Rs m24419,995 1.2%   
Share capital Rs m227531 42.8%   
"Free" reserves Rs m5,44153,043 10.3%   
Net worth Rs m5,66853,574 10.6%   
Long term debt Rs m250-   
Total assets Rs m7,90161,585 12.8%  
Interest coverage x353.3618.4 57.1%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.7 130.1%   
Return on assets %16.517.3 95.8%  
Return on equity %22.919.8 115.9%  
Return on capital %34.026.1 130.5%  
Exports to sales %0.20-   
Imports to sales %36.325.2 144.0%   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,46510,259 24.0%   
Fx inflow Rs m1535,384 0.0%   
Fx outflow Rs m2,67710,399 25.7%   
Net fx Rs m-2,66224,985 -10.7%   
CASH FLOW
From Operations Rs m92311,493 8.0%  
From Investments Rs m317-11,372 -2.8%  
From Financial Activity Rs m-481-93 516.6%  
Net Cashflow Rs m75928 2,672.9%  

Share Holding

Indian Promoters % 0.0 52.0 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 11.8 95.8%  
FIIs % 7.2 19.0 37.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 17.2 176.7%  
Shareholders   21,978 31,796 69.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   PANACEA BIOTECH  DISHMAN PHARMA  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare WYETH LTD With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Metal Stocks Down(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 0.1%.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD - GLENMARK PHARMA COMPARISON

COMPARE WYETH LTD WITH

MARKET STATS